GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Zimmer Holdings, Inc. (ZBH) [hlAlert]

Rating:
Outperform
ZMH
up 10.90 %

Zimmer Holdings, Inc. (ZMH) upgraded to Outperform by Leerink Swann

Posted on: Monday,  Jan 6, 2014  9:25 AM ET by Leerink Swann

Leerink Swann rated Outperform Zimmer Holdings, Inc. (NYSE: ZBH) on 01/06/2014, when the stock price was $93.24.
Since then, Zimmer Holdings, Inc. has gained 10.91% as of 01/12/2016's recent price of $103.41.
If you would have followed this Leerink Swann 's recommendation on ZBH, you would have gained 10.9% of your investment in 736 days.

Zimmer Holdings, Inc. (Zimmer) designs, develops, manufactures and markets orthopaedic and dental reconstructive implants, spinal implants, trauma products and related surgical products. The Company also provides other healthcare related services. Its primary customers include musculoskeletal surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers and, in their capacity as agents, healthcare purchasing organizations or buying groups. These customers range from large multinational enterprises to independent surgeons. It has operations in more than 25 countries and market products in more than 100 countries. In October 2008, the Company acquired Abbott Spine. It markets and sells products through three channels: direct to healthcare institutions, such as hospitals or direct channel accounts; through stocking distributors and, in the Asia Pacific region, healthcare dealers, and directly to dental practices and dental laboratories.

Leerink Swann Equity Research provides unique perspectives and agenda-setting healthcare recommendations for investors. Supported by industry-based intelligence and thorough market examination, our proprietary research enables our clients to make well-informed healthcare investment decisions. Our investment perspectives are driven by proprietary insights from MEDACorp. MEDACorp's more than 25,000 network professionals work with new and/or development-stage pharmaceuticals, medical devices and biotherapeutics on a daily basis. MEDACorp's extensive knowledge of products and research enables Leerink Swann to provide growth-focused clients an expertise earned through experience.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/6/2014 9:25 AM Buy
None
93.24
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/24/2009 8:25 AM Hold
None
44.62 47.00
6/23/2008 8:25 AM Hold
None
68.64 76.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy